AbCellera Biologics (ABCL) Gross Margin (2020 - 2025)

AbCellera Biologics has reported Gross Margin for 6 years, with the latest figure at 67.55% in Q3 2025.

• For the quarter ending Q3 2025, Gross Margin rose 1573.0% year-over-year to 67.55%; the trailing twelve-month figure through Sep 2025 stood at 102.49% (down 190.0% YoY), and the FY2024 full-year result was 100.0%, changed 0.0% from the prior year.
• Gross Margin for Q3 2025 stood at 67.55%, down from 82.39% in the prior quarter.
• The five-year high for Gross Margin was 348.92% in Q4 2022, with the low at 32.89% in Q1 2025.
• Historically, Gross Margin has averaged 107.31% across 5 years, with a median of 82.39% in 2025.
• Annual changes were most pronounced in 2022 — Gross Margin surged 25023 bps — and 2023, when it sank 12821 bps.
• AbCellera Biologics' Gross Margin stood at 98.69% in 2021, then jumped by 254 bps to 348.92% in 2022, then plunged by 37 bps to 220.71% in 2023, then jumped by 32 bps to 290.79% in 2024, then slumped by 77 bps to 67.55% in 2025.
• The last three Gross Margin figures came in at 67.55% (Q3 2025), 82.39% (Q2 2025), and 32.89% (Q1 2025), per Business Quant data.